CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Financial Statements and ExhibitsITEM 9.01
| Exhibit 99.1 | – Press Release dated December 21, 2017 |
CELGENE CORP /DE/ ExhibitEX-99.1 2 tv481914_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Celgene and lysarc PROVIDE UPDATE ON phase iii ‘relevance’ study of revlimid® in combination with rituximab (R2) for the treatment of PREVIOUSLY UNTREATED patients with follicular lymphoma SUMMIT,…To view the full exhibit click here
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.
